The carbon tetrachloride (CCl4)-induced hepatic fibrosis mouse model is widely used to investigate the preclinical efficacy of test compounds in resolving inflammation and hepatic fibrosis. CCl4 is a well-known hepatotoxin which causes oxidative stress and chemical injury. Its biotransformation in the liver produces toxic metabolites like the highly reactive tri-chloro-methyl free radical which is further converted into peroxy-trichloro-methyl radical. These reactive oxidant species likely contribute to the onset and progression of inflammation and fibrosis. Unlike the diet models, the CCl4 model offers a quick phenotype development of hepatic fibrosis and allows investigators to rapidly test their investigative compounds.
Triangulum Biopharma has optimized the CCl4 model in mice and offers preclinical efficacy, proof-of-concept and mechanism of action studies. In addition to the live phase, Triangulum Biopharma also conducts clinical chemistry for liver enzymes, biochemical and ELISA assays, gene expression analysis by qPCR, hydroxyproline assays, histological processing of samples and histopathology.